Satiety signalling refers to the central-nervous-system pathways that integrate peripheral and hormonal inputs into a sensation of fullness that reduces food intake. Key nodes include the nucleus of the solitary tract (NTS) and area postrema in the hindbrain and POMC / NPY-AgRP neurons in the hypothalamic arcuate nucleus.
Both GIP and GLP-1 receptors are expressed at these nodes. Dual GIP / GLP-1 agonists such as Tirzepatide engage more of the satiety network than GLP-1 mono-agonists, which is one hypothesised contributor to the reported effects on food intake in preclinical models.
Satiety signalling is the central-nervous-system substrate through which incretin pharmacology reduces food intake.
